Tags

Type your tag names separated by a space and hit enter

Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience.
BJU Int. 2000 Sep; 86(4):466-8.BI

Abstract

OBJECTIVE

To evaluate prospectively the efficacy of extracorporeal shock wave therapy (ESWT) as a conservative treatment for Peyronie's disease.

PATIENTS AND METHODS

After obtaining ethical committee approval, 37 patients with Peyronie's disease were treated using ESWT. Before treatment the degree of angulation was assessed by artificially inducing an erection with a vacuum device. The severity of pain on erection was assessed using a visual analogue scale (0-5). Each patient was treated with a minimum of three sessions of ESWT (3000 shock waves at an energy density of 0.11-0.17 mJ/mm2) at 3-week intervals. The results were analysed using the Wilcoxon signed-rank test.

RESULTS

Of the 37 patients, 34 completed the protocol; the mean (range) duration of the disease was 19.43 (4-60) months and the mean follow-up 7.5 (5-11) months. Almost half (47%) of the patients reported an improvement in angulation, with a mean reduction of 29.3 degrees (10 degrees -60 degrees) (P < 0.001); 12 of the 20 (60%) patients with pain on erection reported immediate relief, the mean reduction being 2.3 (1-4) on the visual analogue scale (P < 0.001). There was only minimal bruising at the site of treatment and no major side-effects were reported.

CONCLUSION

ESWT is an effective and safe treatment for Peyronie's disease; the long-term follow-up and results are awaited.

Authors+Show Affiliations

Department of Urology, Stepping Hill Hospital, Stockport, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10971273

Citation

Husain, J, et al. "Extracorporeal Shock Wave Therapy in the Management of Peyronie's Disease: Initial Experience." BJU International, vol. 86, no. 4, 2000, pp. 466-8.
Husain J, Lynn NN, Jones DK, et al. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU Int. 2000;86(4):466-8.
Husain, J., Lynn, N. N., Jones, D. K., Collins, G. N., & O'Reilly, P. H. (2000). Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU International, 86(4), 466-8.
Husain J, et al. Extracorporeal Shock Wave Therapy in the Management of Peyronie's Disease: Initial Experience. BJU Int. 2000;86(4):466-8. PubMed PMID: 10971273.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. AU - Husain,J, AU - Lynn,N N, AU - Jones,D K, AU - Collins,G N, AU - O'Reilly,P H, PY - 2000/9/6/pubmed PY - 2001/2/28/medline PY - 2000/9/6/entrez SP - 466 EP - 8 JF - BJU international JO - BJU Int VL - 86 IS - 4 N2 - OBJECTIVE: To evaluate prospectively the efficacy of extracorporeal shock wave therapy (ESWT) as a conservative treatment for Peyronie's disease. PATIENTS AND METHODS: After obtaining ethical committee approval, 37 patients with Peyronie's disease were treated using ESWT. Before treatment the degree of angulation was assessed by artificially inducing an erection with a vacuum device. The severity of pain on erection was assessed using a visual analogue scale (0-5). Each patient was treated with a minimum of three sessions of ESWT (3000 shock waves at an energy density of 0.11-0.17 mJ/mm2) at 3-week intervals. The results were analysed using the Wilcoxon signed-rank test. RESULTS: Of the 37 patients, 34 completed the protocol; the mean (range) duration of the disease was 19.43 (4-60) months and the mean follow-up 7.5 (5-11) months. Almost half (47%) of the patients reported an improvement in angulation, with a mean reduction of 29.3 degrees (10 degrees -60 degrees) (P < 0.001); 12 of the 20 (60%) patients with pain on erection reported immediate relief, the mean reduction being 2.3 (1-4) on the visual analogue scale (P < 0.001). There was only minimal bruising at the site of treatment and no major side-effects were reported. CONCLUSION: ESWT is an effective and safe treatment for Peyronie's disease; the long-term follow-up and results are awaited. SN - 1464-4096 UR - https://wwww.unboundmedicine.com/medline/citation/10971273/Extracorporeal_shock_wave_therapy_in_the_management_of_Peyronie's_disease:_initial_experience_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1464-4096&amp;date=2000&amp;volume=86&amp;issue=4&amp;spage=466 DB - PRIME DP - Unbound Medicine ER -